Survodutide 10mg

Survodutide, developed by Boehringer Ingelheim as BI 456906, is an acylated peptide agonist of the glucagon receptor and the GLP-1 receptor. This listing is a 10 mg vial of freeze-dried powder. Research on survodutide covers how it was chosen from a series of dual agonists, its effects on energy expenditure and food intake in mice, and phase 2 trials in obesity and type 2 diabetes, with phase 3 results published in 2026.

Specifications

What is known about the structure

The site’s guide describes survodutide as a 29-residue peptide built on the glucagon sequence, with substitutions that shift its activity toward the GLP-1 receptor and a non-coded residue among them. Its discovery paper describes it as an acylated peptide carrying a C18 fatty acid, added to extend its half-life¹. The safety data sheet lists CAS number 2805997-46-8 and the formula C192H289N47O61.

This page does not yet carry a lot certificate panel for survodutide, so it gives no theoretical mass, written-out sequence or molar amount for the vial. Those figures belong to the certificate for the lot you receive, and the identity result there is the one to rely on. What purity and identity results show is covered in peptide purity testing.

Handling notes

Survodutide is classified Repr. 2 (H361) on its safety data sheet, meaning it is suspected of damaging fertility or the unborn child, and the sheet asks for it to be kept locked up, closed and labelled. The sealed vial is stored frozen, desiccated and protected from light; the sheet gives −20 °C as the typical temperature for peptides. Allow the vial to warm to room temperature before it is opened, so that water does not condense on the powder. Once reconstituted, the solution is held at 2 to 8 °C in the dark and used within a period your laboratory has established. None of the papers cited here measured survodutide’s stability in solution. Peptide storage and stability covers the general principles.

What the research covers

How it was selected

Survodutide was picked from 19 dual glucagon receptor and GLP-1 receptor agonists². Thomas and colleagues measured cAMP responses in CHO-K1 cells expressing the human receptors, in mouse insulinoma cells for the GLP-1 receptor and in rat primary hepatocytes for the glucagon receptor, then checked receptor engagement in mice: oral glucose tolerance for the GLP-1 receptor, and plasma FGF21 and liver nicotinamide N-methyltransferase (NNMT) mRNA for the glucagon receptor². Across the 19 compounds these in vivo markers correlated with in vitro potency, and survodutide was one of three selected for fuller profiling before it was qualified as the clinical candidate².

Mouse pharmacology

The discovery paper by Zimmermann and colleagues characterised BI 456906 in cell-based assays and in mice¹. In mice it lowered body weight more than semaglutide given at maximally effective levels, and the authors attributed the difference to increased energy expenditure together with reduced food intake¹. They showed engagement of the GLP-1 receptor through glucose tolerance, food intake and gastric emptying tests, and of the glucagon receptor through the liver enzyme NNMT¹. The rationale goes back to oxyntomodulin, a gut peptide that activates both receptors and, in human studies, reduced energy intake and raised energy expenditure¹.

Phase 2 trials

In obesity, le Roux and colleagues ran a randomised, double-blind, placebo-controlled phase 2 trial at 43 centres in 12 countries, in adults aged 18 to 75 with a BMI of 27 or more and no diabetes³. Four survodutide groups were compared with placebo over 46 weeks, with assignment stratified by sex, and the primary endpoint was the percentage change in body weight at week 46³. In type 2 diabetes, Blüher and colleagues randomised 413 adults on metformin, with HbA1c of 7.0 to 10.0% and BMI of 25 to 50, to six survodutide groups, placebo or open-label semaglutide⁴. The primary endpoint there was the change in HbA1c after 16 weeks, with relative change in body weight as the key secondary endpoint⁴. The full analysis set comprised 411 treated participants, and the semaglutide arm was the only one not blinded⁴.

Phase 3 and what is not established

Phase 3 results, including SYNCHRONIZE-1 in obesity and a separate trial in fatty liver disease, were published in 2026 and are covered, with their discontinuation rates, in the mazdutide vs survodutide vs tirzepatide guide. Survodutide is not approved in any country, and no trial has compared it directly with mazdutide, tirzepatide or retatrutide. The abstracts cited here do not give its potency ratio between the two receptors, and the evidence that energy expenditure drives part of its effect comes from mice¹. The human trials used the clinical drug product under medical supervision, and none of the studies involved research-grade material.

How each lot is tested

Every lot is tested in PrymaLab’s own laboratory in Ashland, Kentucky before release: RP-HPLC for purity, LC-MS for identity, Karl Fischer titration for water, LAL for endotoxin and USP <71> for sterility. Published certificates are listed on the results page and can be checked by number and key on the verify page. These are in-house results from PrymaLab Analytical, not an independent test, and the lab is not accredited to ISO 17025. The third-party testing guarantee on this page still applies: if any independent laboratory finds the wrong compound, or less than the stated purity or amount, the order is refunded and the cost of the test is reimbursed.

Frequently asked questions

References

1. Zimmermann T, Thomas L, Baader-Pagler T, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022;66:101633. DOI · PubMed
2. Thomas L, Martel E, Rist W, et al. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection. Diabetes Obes Metab. 2024;26(6):2368-2378. DOI · PubMed
3. le Roux CW, Steen O, Lucas KJ, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162-173. DOI · PubMed
4. Blüher M, Rosenstock J, Hoefler J, et al. Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2024;67(3):470-482. DOI · PubMed